Ekaterina Novosadova

Dr. Ekaterina Novosadova


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2022 in Biology
Verified
Journal Article
Open access
PDF file
Dmitrii MarkovDmitrii Markov
Dmitrii Markov
ENEkaterina Novosadova
Ekaterina Novosadova
Major depressive disorder (MDD) is one of the most common mood disorders worldwide. A lack of understanding of the exact neurobiological mechanisms of depression complicates the search for new effective drugs. Animal models are an important tool in the search for new approaches to the treatment of this disorder. All animal models of depression have certain advantages and disadvantages. We often hear that the main drawback of the chronic unpredictable mild stress (CUMS) model of depression is its poor reproducibility, but rarely does anyone try to find the real causes and sources of such poor reproducibility. Analyzing the articles available in the PubMed database, we tried to identify the factors that may be the sources of the poor reproducibility of CUMS. Among such factors, there may be chronic sleep deprivation, painful stressors, social stress, the difference in sex and age of animals, different stress susceptibility of different animal strains, handling quality, habituation to stressful factors, various combinations of physical and psychological stressors in the CUMS protocol, the influence of olfactory and auditory stimuli on animals, as well as the possible influence of various other factors that are rarely taken into account by researchers. We assume that careful inspection of these factors will increase the reproducibility of the CUMS model between laboratories and allow to make the interpretation of the obtained results and their comparison between laboratories to be more adequate.

1 October 2006 in Brain Research
Verified
Journal Article
Closed access
ODOleg V. Dolotov
Oleg V. Dolotov
EKEkaterina A. Karpenko
Ekaterina A. Karpenko
LILyudmila S. Inozemtseva
Lyudmila S. Inozemtseva
TSTamara S. Seredenina
Tamara S. Seredenina
NLNatalia Levitskaya
Natalia Levitskaya
JEJürgen Engele
Jürgen Engele

Verified
Journal Article
Open access
PDF file
SAStanislav Antonov
Stanislav Antonov
ENEkaterina Novosadova
Ekaterina Novosadova
Human induced pluripotent stem (iPS) cells have the potential to give rise to a new era in Parkinson’s disease (PD) research. As a unique source of midbrain dopaminergic (DA) neurons, iPS cells provide unparalleled capabilities for investigating the pathogenesis of PD, the development of novel anti-parkinsonian drugs, and personalized therapy design. Significant progress in developmental biology of midbrain DA neurons laid the foundation for their efficient derivation from iPS cells. The introduction of 3D culture methods to mimic the brain microenvironment further expanded the vast opportunities of iPS cell-based research of the neurodegenerative diseases. However, while the benefits for basic and applied studies provided by iPS cells receive widespread coverage in the current literature, the drawbacks of this model in its current state, and in particular, the aspects of differentiation protocols requiring further refinement are commonly overlooked. This review summarizes the recent data on general and subtype-specific features of midbrain DA neurons and their development. Here, we review the current protocols for derivation of DA neurons from human iPS cells and outline their general weak spots. The associated gaps in the contemporary knowledge are considered and the possible directions for future research that may assist in improving the differentiation conditions and increase the efficiency of using iPS cell-derived neurons for PD drug development are discussed.

29 October 2016 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
VNValentina Nenasheva
Valentina Nenasheva
ENEkaterina Novosadova
Ekaterina Novosadova
IMI. V. Makarova
I. V. Makarova
OLO. S. Lebedeva
O. S. Lebedeva
MGM. A. Grefenshtein
M. A. Grefenshtein
VTV. Z. Tarantul
V. Z. Tarantul

9 December 2019 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
ENEkaterina Novosadova
Ekaterina Novosadova
VNValentina Nenasheva
Valentina Nenasheva
IMI. V. Makarova
I. V. Makarova
ODOleg V. Dolotov
Oleg V. Dolotov
LIL. S. Inozemtseva
L. S. Inozemtseva
VTV. Z. Tarantul
V. Z. Tarantul

Verified
Journal Article
Open access
PDF file
TGTatiana Gerasimova
Tatiana Gerasimova
Ekaterina StepanenkoEkaterina Stepanenko
Ekaterina Stepanenko
LNLyudmila Novosadova
Lyudmila Novosadova
EAElena Arsenyeva
Elena Arsenyeva
DSDarya Shimchenko
Darya Shimchenko
ENEkaterina Novosadova
Ekaterina Novosadova
Parkinson’s disease (PD) is the second most common neurodegenerative diseases characterized by progressive loss of midbrain dopaminergic neurons in the substantia nigra. Mutations in the PARK2 gene are a frequent cause of familial forms of PD. Sustained chronic neuroinflammation in the central nervous system makes a significant contribution to neurodegeneration events. In response to inflammatory factors produced by activated microglia, astrocytes change their transcriptional programs and secretion profiles, thus acting as immunocompetent cells. Here, we investigated iPSC-derived glial cell cultures obtained from healthy donors (HD) and from PD patients with PARK2 mutations in resting state and upon stimulation by TNFα. The non-stimulated glia of PD patients demonstrated higher IL1B and IL6 expression levels and increased IL6 protein synthesis, while BDNF and GDNF expression was down-regulated when compared to that of the glial cells of HDs. In the presence of TNFα, all of the glial cultures displayed a multiplied expression of genes encoding inflammatory cytokines: TNFA, IL1B, and IL6, as well as IL6 protein synthesis, although PD glia responded to TNFα stimulation less strongly than HD glia. Our results demonstrated a pro-inflammatory shift, a suppression of the neuroprotective gene program, and some depletion of reactivity to TNFα in PARK2-deficient glia compared to glial cells of HDs.